Jacques Mizrahi joined Aravis in 2013 as a consultant acting Venture Partner. Before joining Aravis, Jacques spent 25 years in drug discovery and translational medicine in big Pharma companies, including GSK, Eli Lilly and Roche, where he developed programs in Diabetes, Renal diseases and Cardiovascular diseases, such as congestive heart failure and acute coronary syndrome.
During his last appointment at Roche, he directed the Global Therapy Area of Metabolic and Cardiovascular and previously led the Clinical Research and Exploratory Medicine unit, focusing on translational medicine programs in metabolic and cardiovascular diseases, which included the clinical research on biomarkers and personalised medicine. Jacques is also a consultant for INSERM Tranfer Initiative and ICAN foundation in France.
Jacques trained in the department of physiology and pharmacology at the medical school of the University of Sherbrooke (Canada) and completed his training by spending few years at the INSERM U36 as a post-doctoral fellow.